KLRS
Kalaris Therapeutics Inc·Healthcare
5.30
1.727%(+0.09)
Market OpenLast Updated: — ET
52W L: $2.1452W H: $11.88
KLRS NEWS
globenewswire.com
May 12
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the first quarter ended March 31, 2026 and provided business updates.
globenewswire.com
Mar 17
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027
